INTRODUCTION
============

The exact origin of Crohn disease (CD) and colitis ulcerosa is unknown, but it is widely accepted that the characteristic inflammation in CD, a type of inflammatory bowel disease (IBD), is the result of dysregulated immune interactions between the host and components of the intestinal microbial flora. Many attempts have been made to identify common and uncommon organisms of bacterial, viral, or fungal origin responsible for these diseases. However, valid and reproducible scientific evidence on the identification and confirmation of the most likely candidates is still lacking. Some studies have shown that Candida colonization is associated with several diseases of the gastrointestinal tract \[[@b1-ac-2018-10-15-2]-[@b3-ac-2018-10-15-2]\]. Although the relationship between fungi and CD has not been clearly established, there is some evidence for the possible role of *Candida albicans* in the processes leading to or maintaining inflammation. In numerous patients, the yeast spreads from the gastrointestinal tract to other organs, which explains why a Candida bloodstream infection can lead to devastating disease \[[@b4-ac-2018-10-15-2]\]. CD is chiefly managed using nonoperative treatment. Upon failure of medical management or the development of complications, surgery should be considered \[[@b5-ac-2018-10-15-2]\]. The aim of our study was to evaluate the occurrence of *C. albicans* in the intra-abdominal cavity of patients considered for surgery due to a failure of conservative or immunosuppressive treatment. Although surgery was planned for these patients, they were not in the acute stage of the disease. Patients with an intra-abdominal abscess, neutropenia, or fever were excluded from the study, and patients with right-sided colon cancer were used as a control group.

METHODS
=======

We conducted a retrospective cohort study of consecutive cases of CD admitted to the surgery department of our hospital during 2014--2017. There were 54 patients (34 males and 20 females) with a mean age of 35.4 years (range, 18--57 years) ([Table 1](#t1-ac-2018-10-15-2){ref-type="table"}). All patients were monitored by a gastroenterologist and were recommended for surgery due to a failure of conservative treatment and the occurrence of complications. The duration of monitoring for patients recommended for operation varied from 1 to 10 years. The control group consisted of 31 patients (15 males and 16 females) with a mean age of 68.5 years (range, 24--89 years). Patients with IBD-associated cancer were not included in the control group. Additionally, neither group received bowel preparations with oral antibiotics. Resection of the terminal ileum and caecum followed by a right-sided colectomy was performed using a laparoscopy approach. In cases of limited space and diminished transparency, open laparotomy was performed. At the time of resection, tissue specimens were taken from the outer portion of the terminal ileum wall and adjacent mesenterium in both of groups. All preoperative samples from CD patients positive for *C. albicans* were obtained from either the outer portion of the bowel wall or the adjacent mesenterium not from the lumen of the bowel. In the control group of 31 patients with malignancy, the samples were obtained during surgery under the same conditions and originated from the same outer wall of the bowel and the adjacent mesenterium. The specimens were placed into test tubes filled with 10% glucose under sterile conditions and were immediately sent for microbiological evaluation. Sabouraud-gentamicin-chloramfenicol 2 agar (SGC2) (bioMérieux, Chemin de l'Orme, France) and chromID Candida agar (CAN2) (bioMérieux, Chemin de l'Orme, France) were used to cultivate fungi for 3--5 days in a thermostat (Binder-Merck Inc., Philadelphia, PA, USA) at 37°C. The first evaluation was done after 48 hours, and the second evaluation was performed 10 days after collection of the specimens. When the cultivation was complete, the phyla were identified using a MALDI-TOF MS biotyper (Bruker Daltonics Inc., Billerica, MA, USA). Postsurgical treatment of patients with positive cultures for Candida and yeasts was not included in our study.

The surgeries performed were part of a standard course of treatment, and written consent was obtained from all patients who underwent this procedure. The ethics committee of the Hospital Košice-Šaca, Ltd., 1st Private Hospital, Košice-Šaca approved this study. Additionally, in our hospital we reduce all possible causes of infection through active monitoring.

Mean values with one standard deviation were computed for the relevant data. Comparisons were calculated using Pearson chi-square test, and P-values \< 0.05 were considered significant. All statistical analyses were performed using IBM SPSS Statistics ver. 22.0 (IBM Co., Armonk, NY, USA).

RESULTS
=======

The inflamed mucosa showed typical inflammatory changes in all CD patients. Fungal infections were found in the tissues obtained from the peritoneal cavity of 16 CD patients (29.6%). *C. albicans* was identified in 12 patients (75%), and yeasts were present in 4 patients (25%) ([Table 2](#t2-ac-2018-10-15-2){ref-type="table"}). Other types of fungi and yeast were not identified. Additionally, *C. albicans* was identified in 10 patients from the short-term cultivation. Furthermore, in 4 cases the short-term cultivation and the long-term cultivation were positive for *C. albicans*. The presence of yeasts and *C. albicans* in preoperative samples was simultaneously confirmed on both types of culture media (SGC2 and CAN2). The average age of patients positive for *C. albicans* and yeasts was 31 years. Of the 16 patients with CD who were positive for fungi and yeasts, 10 patients (62.5%) had received immunosuppressive treatment before surgery. Imidazole was administered to a total of 18 patients, but only 5 of those patients were positive for *C. albicans* or yeasts. Infliximab (IFX) was used in 3 patients before surgery, none of whom were positive for *C. albicans* or yeasts. Inflammatory markers (e.g., leukocytosis and C-reactive protein) were elevated in 24 patients (44.4%) with CD. In the group with CD, drug allergy was present in 12 patients (22.2%), food intolerance in 5 patients (9.2%), and extraintestinal symptoms in 2 patients (3.7%) ([Table 1](#t1-ac-2018-10-15-2){ref-type="table"}). In the control group of 31 patients, the presence of fungi and yeasts was confirmed in only 2 cases (6.45%) ([Table 2](#t2-ac-2018-10-15-2){ref-type="table"}). The presence of *C. albicans* in tissue specimens was confirmed using short-term cultivation as well as cultivation in both culture media. Of the patients with CD, resection of the terminal ileum and caecum was performed via laparotomy in 21 cases, laparoscopic resection in 10 patients, and single-incision laparoscopic surgery (SILS) in 14 patients. Right hemicolectomy was performed in 6 cases using laparotomy and in 3 patients using a laparoscopic procedure, but SILS was not used for the right hemicolectomy in either group. In 7 cases, the need to need to change from laparoscopy to laparotomy was due to limited space and diminished transparency. In the control group of patients with a malignancy, we resected the tumor on the right side, eventually extending to a colectomy, using laparotomy in 14 cases and laparoscopy in 17 cases. In that group, there was no need to convert the laparoscopy to laparotomy midsurgery ([Table 3](#t3-ac-2018-10-15-2){ref-type="table"}). In patients of both of group positive for fungal infection, the terminal ileum and caecum were resected using laparotomy in 5 patients, laparoscopy in 3 cases, and SILS resection in 4 cases. In 3 cases a conversion from laparoscopy or SILS to laparotomy was necessary. In cases where only right-sided colectomy was performed, only one patient was positive for fungal cultivation. Using Pearson chi-square test, patients with CD had significantly higher prevalence of fungi and yeast compared with cancer patients (χ^2^ = 4.3873, P \< 0.05) ([Table 4](#t4-ac-2018-10-15-2){ref-type="table"}). There were no differences between the surgical approaches in terms of positive cultivation of fungi and yeasts.

DISCUSSION
==========

A number of prospective observational studies and case reports have been published highlighting the predisposition of patients with IBD for the development of severe infections due to opportunistic and common microbial pathogens \[[@b6-ac-2018-10-15-2], [@b7-ac-2018-10-15-2]\]. Opportunistic infections are infections caused by microorganisms invading a weakened immune system. In cases of immunocompetent hosts, the disease is typically mild or not apparent \[[@b8-ac-2018-10-15-2]\]. Opportunistic infections often are associated with significant morbidity and mortality and may be difficult to treat effectively \[[@b9-ac-2018-10-15-2]\]. Opportunistic infections are common in patients with CD and colitis ulcerosa and have been described previously in retrospective case reports, case series \[[@b7-ac-2018-10-15-2], [@b10-ac-2018-10-15-2]-[@b14-ac-2018-10-15-2]\], and prospective clinical trials of new therapies for IBD \[[@b15-ac-2018-10-15-2]-[@b17-ac-2018-10-15-2]\]. In our study, bowel perforation and abscess did not occur before surgery. Instead, the patients were scheduled for routine surgery, and it was difficult to retrospectively correlate the development of fistulae with intra-abdominal fungal infections. The European Crohn's and Colitis Organisation states that all patients with IBD on corticosteroids, immunomodulators, or biological agents should be considered as immunocompromised and at risk for opportunistic infections \[[@b18-ac-2018-10-15-2]\]. Of the 3 patients treated with IFX, none were positive for yeasts or *C. albicans* and treatment with imidazole was not followed increased occurrence of fungi infections. Of the 18 patients treated with imidazole, only 5 were positive for *C. albicans* or yeasts (27%). The risk factors and outcomes of opportunistic infections in IBD patients have not been well evaluated. Nonetheless, neutropenia is considered a predisposing factor for opportunistic infection with bacterial opportunists such as Pseudomonas aeruginosa and opportunistic fungi such as *Candida* and *Aspergillus*. Although there were no patients with neutropenia or fever in either group in this study, the identification of IBD patients at risk for serious opportunistic infections is important to optimize patient outcomes through the development of prophylactic or preemptive strategies \[[@b8-ac-2018-10-15-2]\]. However, despite the fact that specific drugs, including corticosteroids, AZA/6MP, and IFX, are associated with specific opportunistic infections, many of these infections were also present in patients not taking those specific drugs \[[@b8-ac-2018-10-15-2]\]. CD patients are more frequently and more heavily colonized by *C. albicans* than healthy subjects\[[@b19-ac-2018-10-15-2]\], and anti-*Saccharomyces cerevisiae* antibodies are present in 50%--60% of CD patients \[[@b20-ac-2018-10-15-2]\]. Invasive Candida infections are primarily caused by 4 species: *C. albicans*, *Candida glabrata*, *Candida parapsilosis*, and *Candida tropicalis* \[[@b21-ac-2018-10-15-2]\]; however, only *C. albicans* was found in this study. Immunosuppression in IBD is associated with oral, oesophageal, or systemic candidiasis, although there is currently no specific recommendation for screening or prophylaxis \[[@b18-ac-2018-10-15-2]\]. In 2009, the TREAT (The Crohn´s Therapy, Resource, Evaulation and Assessement Tool) registry reported 4 cases of systemic candidiasis, diagnosed from cultures of blood or the affected site \[[@b18-ac-2018-10-15-2], [@b21-ac-2018-10-15-2]\], in patients with CD over a 5-year follow-up, of which 3 patients were treated with infliximab and 1 was treated with an immunomodulator. In contrast, IFX use in the preoperative period was not associated with an increase in total, infectious, or noninfectious complications in 734 patients with UC undergoing abdominal surgery according to a long-term follow-up study by Fidder et al. \[[@b22-ac-2018-10-15-2]\]. However, for the IFX-treated patients presenting with infections, corticosteroid treatment was an independent risk factor. In our study, there was a significantly higher rate of extraintestinal Candida infections in comparison with the control group of cancer patients. Stress-induced increased intestinal permeability may occur in healthy controls as well as in IBD patients \[[@b23-ac-2018-10-15-2]-[@b27-ac-2018-10-15-2]\] and can be seen in other chronic inflammatory disorders like asthma and coeliac disease \[[@b28-ac-2018-10-15-2], [@b29-ac-2018-10-15-2]\]. While the inflamed ileal mucosa from patients with CD did not differ from those of the control group with colonic cancer, inflamed specimens typically show significantly increased permeability \[[@b30-ac-2018-10-15-2]\]. In this study, we found a significant difference in the cultivation rates from abdominal cavity of CD patients compared to the control group of patients with cancer. This suggests that patients with IBD may be at a higher risk for opportunistic infections, which is significantly increased when patients take immunosuppressants \[[@b8-ac-2018-10-15-2]\]. However, it is important to determine whether Candida infection causes or is a consequence of a chronic course. Although no complications occurred in connection with sampling for cultivation, we have interrupted our research so that we can fully evaluate the results to date, and we plan to continue this research in the future.

In conclusion, the patients with IBD may be at risk of opportunistic infections that can substantially influence mortality and morbidity. Our study showed a significantly higher rate of extra-intestinal, but not intraluminal, Candida infections in the abdominal cavity of CD patients compared to the control group of patients with colon cancer at the time of surgery. However, there is a need for further evaluation of the role of fungal infections in CD and their influence on course of this entity.
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###### 

Cohort of patients

  Variable                                                              Crohn disease (n = 54)   Control group (n = 31)   χ^2^    P-value
  --------------------------------------------------------------------- ------------------------ ------------------------ ------- ---------
  Sex                                                                                                                     1.714   0.191
   Male                                                                 34 (63.0)                15 (48.4)                        
   Female                                                               20 (37.0)                16 (51.6)                        
  Average age (yr)                                                      35.4                     68.5                             
   Male                                                                 34.8                     \-                               
   Female                                                               36.8                     \-                               
  Immunosuppressive treatment                                           32 (59.3)                0 (0)                            
  Immunosuppressive treatment (16 patients with positive cultivation)   10 (62.5)                \-                               
  Positive inflammatory markers                                         24 (44.4)                \-                               
  Drug allergy                                                          12 (22.2)                \-                               
  Food intolerance                                                      5 (9.2)                  \-                               
  Extraintestinal symptoms                                              2 (3.7)                  \-                               

Values are presented as number (%) unless otherwise indicated.

###### 

Cultivation results

  Variable                   Crohn disease (n = 54)   Control group (n = 31)   χ^2^    P-value
  -------------------------- ------------------------ ------------------------ ------- ---------
  Positive cultivation       16 (29.6)                2 (6.45)                 6.338   0.012
   *Candida albicans*        12 (75.0)                2 (100)                  3.560   0.059
    Short-term cultivation   10                       2                        2.365   0.124
    Long-term cultivation    12                       2                        3.560   0.059
   Yeasts                    4 (25.0)                 0 (0)                    NA      
    Short-term cultivation   4                        0                        NA      
    Long-term cultivation    4                        0                        NA      

Values are presented as number (%) unless otherwise indicated.

NA, not applicable.

###### 

Surgery types

  Surgery type                          Crohn disease (n = 54)   Control group (n = 31)   χ^2^     P-value
  ------------------------------------- ------------------------ ------------------------ -------- -----------
  Terminal ileum and caecum resection                                                              
   Laparotomy                           14 (25.9)                \-                       NA       
   Conversion                           7 (12.9)                 \-                       NA       
   Laparoscopy                          10 (18.5)                \-                       NA       
   SILS                                 14 (25.9)                \-                       NA       
  Right-sided colectomy                                                                            
   Laparotomy                           6 (11)                   14 (45.2)                12.69    0.0003
   Laparoscopy                          3 (5.5)                  17 (54.8)                26.584   0.0000001
   SILS                                 0 (0)                    0 (0)                             

Values are presented as number (%) unless otherwise indicated.

SILS, single incision laparoscopic surgery; NA, not applicable.

###### 

Statistical analysis of fungi- and yeast-positivity

  Group           Candida-negative (n = 85)   Candida-positive (n = 18)   Total (n = 103)
  --------------- --------------------------- --------------------------- -----------------
  Crohn disease   54 (57.77%)                 16 (12.23%)                 70 (100%)
  Cancer          31 (27.23%)                 2 (5.77%)                   33 (100%)

The chi-square value is 4.3873. The P-value is 0.036. This result is significant at P \< 0.05.
